Santen Pharmaceutical Co., Ltd.
SNPHYOTCHealthcare● Active
$12.15
+$0.40(+3.38%)
Market Cap$3.9B
P/E Ratio—
52W High$12.68
52W Low$9.22
Santen Pharmaceutical Co., Ltd. (SNPHY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SNPHY · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $309.21B | $300.00B | $301.96B | $279.04B | $266.26B |
| Cost of Revenue | $138.53B | $128.98B | $123.26B | $112.95B | $109.67B |
| Gross Profit | $170.68B | $171.03B | $178.71B | $166.09B | $156.59B |
| Gross Margin %(computed) | 55.20% | 57.01% | 59.18% | 59.52% | 58.81% |
| Operating Expenses | |||||
| R&D Expenses | $27.76B | $24.10B | $25.42B | $28.30B | $26.38B |
| G&A Expenses | $0.00B | $87.97B | $91.53B | $96.26B | $84.50B |
| Total Operating Expenses | $122.74B | $124.15B | $140.17B | $169.18B | $120.70B |
| Operating Income | $47.94B | $46.88B | $38.54B | ($3.09B) | $35.89B |
| Operating Margin %(computed) | 15.50% | 15.63% | 12.76% | -1.11% | 13.48% |
| Interest Income | $1.74B | $4.00B | $1.57B | $1.15B | $2.54B |
| Interest Expense | $2.11B | $2.72B | $2.66B | $1.50B | $1.21B |
| Income Before Tax | $50.30B | $47.48B | $29.87B | ($5.80B) | $35.62B |
| Income Tax Expense | $10.48B | $11.63B | $3.17B | $9.18B | $8.43B |
| Net Income | $39.62B | $36.26B | $26.64B | ($14.95B) | $27.22B |
| Net Margin %(computed) | 12.81% | 12.09% | 8.82% | -5.36% | 10.22% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $121.43 | $103.98 | $72.62 | $-38.58 | $68.07 |
| Wtd Avg Shares | 0.33B | 0.35B | 0.37B | 0.39B | 0.40B |
| EBITDA | $67.41B | $59.01B | $50.72B | $12.95B | $52.93B |
| EBITDA Margin %(computed) | 21.80% | 19.67% | 16.80% | 4.64% | 19.88% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · JPY · B
Explore more Santen Pharmaceutical Co., Ltd. data
About Santen Pharmaceutical Co., Ltd. (SNPHY) Income Statement
Santen Pharmaceutical Co., Ltd. (SNPHY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2026, SNPHY reported revenue of $309.21B, gross profit of $170.68B (gross margin 55.20%), and net income of $39.62B — a net profit margin of 12.81%.
Frequently asked questions
SNPHY · 4 questionsSanten Pharmaceutical Co., Ltd. (SNPHY) reported revenue of $309.21B for 2026, up 3.1% year-over-year.
SNPHY revenueSNPHY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08